Breaks Categories: Stock Spotlights

WednesdayOct 19, 2016 12:32 pm

Monaker Group, Inc.’s (MKGI) Maupintour Occupies Long-standing Position in Luxury Travel Market

The luxury travel market experienced a compound annual growth rate of 4.5% between 2011 and 2015, an upward trend expected to continue as more consumers pursue personalized experiences and top-notch services. The trend is likely to continue over the next decade, with new business opportunities and challenges for leading providers of luxury tours such as Monaker Group, Inc.’s (OTCQB: MKGI) Maupintour …a company with 65 years of experience in offering luxury and customizable private tours to the best destinations in the world. Some of the top luxury tours on the company’s roster this fall include a 9-day tour of traditional…

Continue Reading

WednesdayOct 19, 2016 12:31 pm

Consumer Trends are Front and Center for Moxian, Inc. (MOXC)

Moxian (OTCQB: MOXC), a provider of social media marketing and promotion platforms, focuses on consumer behavior to help merchants better understand buyers’ decision making processes. “With consumer behavior data being at the forefront of e-commerce today, the goal is to know what consumers want before they even ask for it. Algorithms and big data are now enabling retailers to capitalize on their consumers by offering them what they want based on their shopping history and all the other variables … MOXC enables consumers and merchants to better interact thanks to consumer behavior data compiled in the Moxian database. With this…

Continue Reading

WednesdayOct 19, 2016 12:28 pm

Cerulean Pharma (CERU) Higher on $20M Purchase Agreement with Aspire Capital, Announces Novartis (NVS) Collaboration

Cerulean Pharma (NASDAQ: CERU) is trading higher following the effect of a $20 million common stock purchase agreement and a registration rights agreement with Aspire Capital Fund, LLC. Immediately following the execution of the purchase agreement, announced this morning, Aspire purchased 800,000 shares of common stock for $1.25 per share. The clinical-stage company developing nanoparticle-drug conjugates (NDCs) also this morning announced its strategic collaboration with Novartis (NYSE: NVS) to develop NDC product candidates combining Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds directed at up to five targets. To view the full press releases, visit: http://nnw.fm/0Wzlg and http://nnw.fm/k20QU…

Continue Reading

TuesdayOct 18, 2016 1:38 pm

Singlepoint, Inc. (SING) Maintains Sharp Focus on Opportunities within Vertical Markets

Singlepoint (OTC: SING) provides mobile technologies and payment solutions, participating in a competitive market dominated by bellwether brands. The company maintains its competitive edge by focusing on underserved verticals with significant potential. Its “Pay-by-Text combination of text messages and payments allows merchants to offer simpler mobile payment options to their customers … SinglePoint is currently in the process of leveraging this technology in two niche markets – daily fantasy sports and mobile auctions, markets where the holding company has purchased minority stock recently. The DFS vertical in particular is expected to bring significant value to the company, due to its…

Continue Reading

TuesdayOct 18, 2016 1:36 pm

OurPet’s Company (OPCO) to Showcase Industry Innovation at MicroCap Conference

OurPet's (OTCQX: OPCO), a trend-setting pet products and accessories company selling its products domestically and internationally under the OurPets® and Pet Zone® brands, this morning said it will present at this year’s MicroCap Conference. Company Chief Financial Officer Scott Mendes will make his presentation on October 25 from 5-5:30 p.m. to showcase the company's innovative pet products and accessories sold through leading pet specialty and Internet retailers, direct-mail catalog, and food, drug and mass merchandisers. To view the full press release, visit: http://nnw.fm/7uJtL About the OurPet's Company The OurPet's Company (OTCQX: OPCO) designs, produces and markets a broad line of…

Continue Reading

TuesdayOct 18, 2016 1:35 pm

Cogint, Inc. (COGT) Trades Higher on Q3 Preliminary Results

Cogint, Inc. (NASDAQ: COGT) shares are up 11% in morning trade after the data and analytics company announced preliminary estimates of financial results for the third quarter ended September 30, 2016. The company estimates third-quarter revenue of approximately $51 million to $52 million, a 24% increase over the second quarter of 2016. Gross profit margins are estimated to be in the range of 24% to 26%. Based on “various trends,” the company said it expects revenue for full year 2016 to be in the range of $183 million to $187 million, and revenue for full year 2017 to be in…

Continue Reading

MondayOct 17, 2016 1:18 pm

MTBC’s (MTBC) Recent Acquisition is Corporate Milestone and Catalyst for Growth

MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a provider of proprietary web-based electronic health records, practice management and mHealth solutions, recently closed its largest acquisition to-date, and provided the investment community with additional details of the deal. Highlights of the MediGain acquisition include: the acquired accounts in good standing have annual revenues of more than $10 million, which will contribute to MTBC's overall revenue growth in 2017; the acquisition is expected to be accretive to MTBC shareholders in 2017; MediGain assets were purchased at a significant discount to the industry norm; the deal expands MTBC’s Asia-based team. To view the full press…

Continue Reading

ThursdayOct 13, 2016 1:34 pm

OncoGenex Pharmaceuticals, Inc. (OGXI) Down 9% on Disappointing Phase 3 ENSPIRIT Trial Results

OncoGenex Pharmaceuticals (NASDAQ: OGXI) shares slid more than 9% in Thursday’s mid-day trade following the company’s morning announcement that its phase 3 ENSPIRIT trial of custirsen in patients whose non-small cell lung cancer (NSCLC) did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with docetaxel compared to docetaxel alone.  Safety results were consistent with those observed in previous trials of custirsen in combination with chemotherapy. To view the full press release, visit:  http://nnw.fm/X5x4V About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of…

Continue Reading

ThursdayOct 13, 2016 1:31 pm

iGambit, Inc. (IGMB) Successes Driven by Top Management

iGambit, Inc. (OTCQB: IGMB) is a diversified holding company focused primarily on the acquisition of early-stage technology firms. The experience and past endeavors of IGMB’s management team bodes well for the company, whose most recent acquisition was named as a ‘Top 20 Enterprise Security Company of 2016’ by leading IT publication CIOReview. IGMB Chairman John Salerno has more than 40 years of experience in the technology industry, while CEO Rory Welch has more than 20 years of senior management in a variety of industries. To view the full article, visit: http://nnw.fm/VzV1N About iGambit Inc. iGambit (OTCQB: IGMB) is a fully…

Continue Reading

WednesdayOct 12, 2016 1:52 pm

Moxian, Inc. (MOXC) Technology Designed to Optimize Social Media for Consumer Engagement

Social media has had a profound impact on the way businesses reach and engage with existing and potential customers. Proper use of the tool hits numerous key aspects of consumer engagement and satisfaction, including customer service, product information, advertising and more. Social customer relationship management (CRM) programs, such as the one developed for the Chinese market by Moxian, Inc. (OTCQB: MOXC) can play a vital role in streamlining the possibilities and tracking pertinent information to better build an engagement strategy. To view the full article, visit: http://nnw.fm/DkVq3 About Moxian, Inc. Moxian engages in the business of providing social marketing and…

Continue Reading